Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
Histone deacetylase plays an important role in HIV latency. Novel histone deacetylase inhibitors, CG05 and CG06, were evaluated for their roles in HIV latency using ACH2 cells. Both inhibitors were highly efficient in reactivation of provirus and exerted lesser toxicity compared with other known histone deacetylase inhibitors. Histone acetylation increased when proviruses were reactivated by the compounds. These new inhibitors may contribute to the reduction of the HIV reservoir when used in conjunction with highly active antiretroviral therapy.
Choi
Byeong-Sun
BS
Division of AIDS, Center for Immunology and Pathology, Korea National Institute of Health, 194 Tongillo, Eunpyung-gu, Seoul, Republic of Korea.
Lee
Hak Sung
HS
Oh
You-Take
YT
Hyun
Young-Lan
YL
Ro
Sunggu
S
Kim
Sung Soon
SS
Hong
Kee-Jong
KJ
D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D014775:Virus Activation / Q000187:drug effects; D017735:Virus Latency / Q000187:drug effects* / Q000235:genetics
D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases